公开(公告)号：EP1648507A1

公开(公告)日：2006-04-26

申请号：EP04744267.8

申请日：2004-07-23

申请人： Innate Pharma ,  Universita Degli Studi Di Perugia

发明人： VELARDI, Andrea ,  ROMAGNE, François

IPC分类号： A61K39/395 ,  G01N33/50

CPC分类号： C07K16/2803 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2887 ,  C07K16/2893 ,  C07K16/2896 ,  C07K2317/732 ,  C07K2317/76 ,  C12N5/0646 ,  G01N33/5047 ,  G01N2333/70535 ,  G01N2500/10

摘要： The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.

公开(公告)号：EP1648508A1

公开(公告)日：2006-04-26

申请号：EP04769123.3

申请日：2004-07-23

申请人： Universita Degli Studi Di Perugia

发明人： VELARDI, Andrea

IPC分类号： A61K39/395

CPC分类号： A61K35/17 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/24 ,  C12N5/0646

摘要： The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with alloreactive natural killer cells in order to enhance the efficiency of the treatment with therapeutic antibody in human subjects.

公开(公告)号：EP1648507B1

公开(公告)日：2017-01-25

申请号：EP04744267.8

申请日：2004-07-23

申请人： Innate Pharma S.A.

发明人： VELARDI, Andrea ,  ROMAGNE, François

IPC分类号： C07K16/28

CPC分类号： C07K16/2803 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2887 ,  C07K16/2893 ,  C07K16/2896 ,  C07K2317/732 ,  C07K2317/76 ,  C12N5/0646 ,  G01N33/5047 ,  G01N2333/70535 ,  G01N2500/10

摘要： The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.

摘要翻译： 本发明涉及，基因反弹，用于增加治疗性抗体的效率的方法和组合物。 他们的效率是通过ADCC机制的增加而增强。 更具体地，本发明涉及联合使用的治疗性抗体与化合物确实抑制性受体的块或刺激，以便增强与在人受试者中的治疗性抗体治疗的效率激活NK细胞的受体。